Arbutus Biopharma Corp

Arbutus Biopharma Corporation held its 2026 Annual General and Special Meeting of Shareholders, where several key proposals were approved. Shareholders adopted the 2026 Omnibus Share and Incentive Plan, authorizing the issuance of 16,300,000 common shares. Additionally, all five director nominees were elected, executive compensation was approved on an advisory basis, and Ernst & Young LLP was appointed as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Arbutus Biopharma reported a significant financial turnaround in Q1 2026, driven by an anticipated $178.7M payment from a settlement agreement with Moderna. The company posted a net income of $169.7M, a substantial improvement from a loss of $24.5M in the prior year's quarter, with total revenue reaching $179.1M. Arbutus also maintained $95.2M in cash, cash equivalents, and marketable securities, and continues its patent litigation against Pfizer/BioNTech while holding global rights for imdusiran.

Arbutus Biopharma Corporation reported strong first quarter 2026 financial results, driven by an estimated $178.7 million in license revenue from Genevant related to the Moderna litigation settlement. The company posted a net income of $169.7 million, a significant turnaround from a net loss in the prior year. Additionally, the FDA granted Fast Track designation to imdusiran for the treatment of chronic hepatitis B, potentially accelerating its development and review.

Arbutus Biopharma reported a net income of $169.7 million for Q1 2026, a significant turnaround from a $24.5 million net loss in Q1 2025. This was primarily driven by a $950 million upfront settlement with Moderna related to LNP patent infringement litigation, from which Arbutus expects to receive an estimated $178.7 million in July 2026. Additionally, the FDA granted Fast Track designation to imdusiran for chronic hepatitis B treatment, aiming to expedite its development and review.

Arbutus Biopharma Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational therapy, imdusiran. This designation is for the treatment of chronic hepatitis B, a serious condition with unmet medical needs. The Fast Track program aims to facilitate the development and expedite the review process for such therapies, potentially accelerating imdusiran's path to market.